Histogenics Corporation, a Waltham, Massachusetts-based regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, priced its underwritten initial public offering of 5,909,091 shares of its common stock at a price to the public of $11.00 per share.
The shares began trading on the NASDAQ Global Market under the ticker symbol “HSGX” on December 3.
Led by Patrick O’Donnell, President and CEO, Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Its first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
The company was backed by Altima Partners, BioMed Ventures, Boston Millennia Partners, FinTech GIMV Fund, Foundation Medical Partners, Histogenics, Inflection Point Capital, ProChon Holdings, Sofinnova Ventures, and Split Rock Partners.
It is hiring a microbiologist.
Cowen and Company, LLC, Needham & Company, LLC and Canaccord Genuity Inc. are acting as the joint book-running managers and BTIG, LLC is acting as co-manager for the offering.